Contrast-enhanced MRI could predict response of systemic therapy in advanced intrahepatic cholangiocarcinoma

被引:6
作者
Sheng, Ruofan [1 ,2 ]
Huang, Xiaoyong [4 ]
Jin, Kaipu [1 ,3 ]
Gao, Shanshan [1 ,3 ]
Zeng, Mengsu [1 ,3 ]
Wu, Dong [1 ,3 ]
Shi, Guoming [4 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Radiol, 180 Fenglin Rd, Shanghai 200032, Peoples R China
[2] Fudan Univ, Zhongshan Xiamen Hosp, Shanghai, Peoples R China
[3] Shanghai Inst Med Imaging, Shanghai, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Liver Surg, Shanghai, Peoples R China
关键词
Magnetic resonance imaging; Cholangiocarcinoma; Combination treatment; HEPATOCELLULAR-CARCINOMA; MICROVASCULAR INVASION; SORAFENIB; CANCER;
D O I
10.1007/s00330-022-08679-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective To investigate whether pre-treatment contrast-enhanced MRI could predict the therapeutic response of systemic treatment in advanced intrahepatic cholangiocarcinoma (ICC). Methods This retrospective study enrolled 61 ICC participants with contrast-enhanced MRI before combined systemic therapy. Clinical characteristics and MRI features were compared between patients with and without therapeutic response by univariate and multivariate logistic regression analyses. Then, a combined MRI-based model and the nomogram were established based on the results of the multivariate analysis. The diagnostic performances of significant findings and the combined model were evaluated and compared. The progression-free survival (PFS) rates between patients with high and low combined index values were compared. Results Thirty (49.18%) patients showed overall response after therapy. In multivariate analysis, tumor margin (odds ratio (OR) = 5.004, p = 0.014), T2 homogeneity (OR = 14.93, p = 0.019), and arterial peritumoral enhancement (OR = 5.076, p = 0.042) were independent predictive factors associated with therapeutic response. The C-index with the formulated nomogram incorporating the three independent imaging features was 0.828 (95% CI 0.710-0.913). Diagnostic characteristics of the combined index were superior to any single feature alone (p = 0.0007-0.0141). ICCs with high combined index values showed higher PFS rates than those with low values (chi(2) = 13.306, p < 0.0001). Conclusions Pre-treatment contrast-enhanced MRI can be used to predict therapeutic response in advanced ICC with systemic therapy. The combination model incorporating significant MRI features achieved an improved predictive value, which may play an important role in identifying appropriate therapeutic candidates.
引用
收藏
页码:5156 / 5165
页数:10
相关论文
共 28 条
[1]   Molecular heterogeneity in intrahepatic cholangiocarcinoma [J].
Ahn, Keun Soo ;
Kang, Koo Jeong .
WORLD JOURNAL OF HEPATOLOGY, 2020, 12 (12) :1148-1157
[2]   Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma [J].
Bertuccio, Paola ;
Malvezzi, Matteo ;
Carioli, Greta ;
Hashim, Dana ;
Boffetta, Paolo ;
El-Serag, Hashem B. ;
La Vecchia, Carlo ;
Negri, Eva .
JOURNAL OF HEPATOLOGY, 2019, 71 (01) :104-114
[3]   Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine? [J].
Braconi, Chiara ;
Roessler, Stephanie ;
Kruk, Beata ;
Lammert, Frank ;
Krawczyk, Marcin ;
Andersen, Jesper B. .
LIVER INTERNATIONAL, 2019, 39 :32-42
[4]   Noninvasive prediction of HCC with progenitor phenotype based on gadoxetic acid-enhanced MRI [J].
Chen, Jie ;
Wu, Zhenru ;
Xia, Chunchao ;
Jiang, Hanyu ;
Liu, Xijiao ;
Duan, Ting ;
Cao, Likun ;
Ye, Zheng ;
Zhang, Zhen ;
Ma, Ling ;
Song, Bin ;
Shi, Yujun .
EUROPEAN RADIOLOGY, 2020, 30 (02) :1232-1242
[5]   Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤ 5 cm [J].
Chong, Huan-Huan ;
Yang, Li ;
Sheng, Ruo-Fan ;
Yu, Yang-Li ;
Wu, Di-Jia ;
Rao, Sheng-Xiang ;
Yang, Chun ;
Zeng, Meng-Su .
EUROPEAN RADIOLOGY, 2021, 31 (07) :4824-4838
[6]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[7]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502
[8]   Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial [J].
Finn, Richard S. ;
Ryoo, Baek-Yeol ;
Merle, Philippe ;
Kudo, Masatoshi ;
Bouattour, Mohamed ;
Lim, Ho Yeong ;
Breder, Valeriy ;
Edeline, Julien ;
Chao, Yee ;
Ogasawara, Sadahisa ;
Yau, Thomas ;
Garrido, Marcelo ;
Chan, Stephen L. ;
Knox, Jennifer ;
Daniele, Bruno ;
Ebbinghaus, Scot W. ;
Chen, Erluo ;
Siegel, Abby B. ;
Zhu, Andrew X. ;
Cheng, Ann-Lii .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (03) :193-+
[9]   Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review [J].
Fiteni, Frederic ;
Nguyen, Thierry ;
Vernerey, Dewi ;
Paillard, Marie-Justine ;
Kim, Stefano ;
Demarchi, Martin ;
Fein, Francine ;
Borg, Christophe ;
Bonnetain, Franck ;
Pivot, Xavier .
CANCER MEDICINE, 2014, 3 (06) :1502-1511
[10]   The State of Immunotherapy in Hepatobiliary Cancers [J].
Ilyas, Farhan Z. ;
Beane, Joal D. ;
Pawlik, Timothy M. .
CELLS, 2021, 10 (08)